X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Full data set supports long-term use of Veltassa® (patiromer) to control potassium buildup (hyperkalemia) in heart failure patients while on guideline-recommended renin-angiotensin-aldosterone system inhibitor therapy.
Lead Product(s): Patiromer
Therapeutic Area: Nephrology Product Name: Veltassa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
Veltassa (patiromer), Phase-IIIb diamond trial demonstrates statistically significant outcome on the primary endpoint and, enabled 85% of patients to be optimized to guideline-recommended doses of RAASi.
Lead Product(s): Patiromer
Therapeutic Area: Nephrology Product Name: Veltassa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2021
Details:
Vifor Pharma continues to drive evidence-based care using Veltassa® through multiple additional trial activities. phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints.
Lead Product(s): Patiromer
Therapeutic Area: Nephrology Product Name: Veltassa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
Details:
CARE-HK in HF is designed to evaluate the use of Veltassa® in enabling patients to remain on RAASi therapy in HF patients with or at high risk for HK.
Lead Product(s): Patiromer
Therapeutic Area: Nephrology Product Name: Veltassa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2021
Details:
Fresenius Kabi will have the exclusive right to distribute and sell Veltassa® across China. By bringing Veltassa® to China, VFMCRP and Fresenius Kabi will deliver a treatment that will enable patients to remain on RAASi therapy by managing their chronic hyperkalemia.
Lead Product(s): Patiromer
Therapeutic Area: Nephrology Product Name: Veltassa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fresenius Kabi AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
